 Can-Fite BioPharma Ltd NYSE: CANF announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week cycle of treatment with Piclidenoson at the beginning of January 2022. Piclidenoson is a novel, first-in-class A3 adenosine receptor agonist A3AR small molecule. 